FINWIRES · TerminalLIVE
FINWIRES

Eaton Datacenter Orders Surge, Growth Outlook Strengthens Into H2, RBC Says

By

-- Eaton (ETN) is executing well across datacenters, utility and electrification, with strong order momentum and backlog growth supporting an expected pickup in organic volume, operating leverage and margin expansion in H2, RBC Capital Markets said.

Datacenter demand was a standout, with orders rising 240% year on year, alongside strong backlog growth across segments. Electrical Americas backlog increased 44%, Electrical Global backlog rose 73% and the order pipeline expanded 81%, the brokerage said in a Tuesday note.

The outsized contraction in Electrical Americas margins in Q1 was attributed to capacity ramps and commodity inflation in steel, copper, aluminum and silver ahead of April 1 price increases. However, the Boyd Thermal acquisition is tracking above its previously guided $1.7 billion full-year sales, potentially adding upside, RBC said.

The firm described the margin pressure as a "high-quality problem" tied to accelerating backlog and capacity expansion.

The company's plan to spin off its Vehicle and eMobility segments by end of Q1 2027 is expected to further shift Eaton's mix toward higher-growth datacenter and aerospace exposure, according to the note.

RBC reiterated its outperform rating on the stock and boosted its price target to $484 per share from $457.

Price: $418.82, Change: $+7.96, Percent Change: +1.94%

Related Articles

Australia

Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says

Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%

$APTV$F
Research

Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target

Price: $15.79, Change: $-4.34, Percent Change: -21.55%

$CRTO
Australia

Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says

Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%

$OCUL